Stock data
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX) reported net income of -US$17.30M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$17.27M | -US$17.30M | — |
| 2024 | — | — | -US$21.64M | -US$19.79M | — |
| 2023 | — | — | -US$16.81M | -US$10.01M | — |
| 2022 | — | — | -US$23.09M | -US$17.75M | — |
| 2015 | — | — | -US$30.58M | -US$45.32M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$4.81M | — |
| 2026-03-31 | — | -US$14.46M | — |
| 2025-12-31 | — | -US$5.30M | — |
| 2025-09-30 | — | -US$6.40M | — |
| 2025-06-30 | — | -US$1.90M | — |
| 2025-03-31 | — | -US$3.71M | — |
| 2024-12-31 | — | -US$3.77M | — |
| 2024-09-30 | — | -US$2.90M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.